BioCentury
ARTICLE | Emerging Company Profile

IDRx: Borisy, Auspitz aim for precision combos that thwart cancers’ escape mechanisms 

Start-up has $122M for first-in-human trials addressing c-Kit-driven GIST, with molecules from Blueprint, Merck KGaA

By Paul Bonanos, Associate Editor
August 2, 2022 8:58 PM UTC

Co-founded by Alexis Borisy and Ben Auspitz, newly launched IDRx will test the thesis that certain precision cancer combinations can lead to clinical benefits far more durable than previously seen, first by pairing in-licensed molecules from Blueprint and Germany’s Merck.

Andreessen Horowitz and Casdin Capital led the $122 million series A round for IDRx Inc., with which the start-up will test a combination therapy for gastrointestinal stromal tumors (GIST)...